ADJUVANT COMPARISON AND CHARACTERIZATION

佐剂比较和表征

• 批准号: 10934821
• 负责人: BALI PULENDRAN
• 金额: $ 279.72万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10934821
• 关键词: Adjuvant; Allergens; Allergic Disease; Animal Model; Animals; Antigens; Autoimmune Diseases; Basic Science; Cells; Collaborations; Communicable Diseases; Communities; Contractor; Data; Development; Disease; Disease Outcome; End Point Assay; Fingerprint; Future; Goals; Human; Immune; Immunity; Immunologics; Innate Immune Response; Measures; National Institute of Allergy and Infectious Disease; Protocols documentation; Side; Site; Standardization; Tissues; Vaccines; Work; adaptive immune response; clinically relevant; data management; novel vaccines; pathogen; programs; research and development; vaccine development

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms and have potential for a given antigen and/or disease target. Contractors supported through the ACC program will be expected to: 1) collaborate with each other, including using standardized protocols or endpoint assays; 2) screen additional adjuvants at the direction of NIAID; and 3) share both positive and negative results in order to help guide basic research and vaccine development activities within the program and across the broader scientific community. In addition, data generated from ACC-supported studies will be made publicly available, enabling the rational selection of adjuvants and the future development of more effective vaccines against infectious diseases, and/or new vaccines to treat allergic or autoimmune diseases.

佐剂比较和表征 (ACC) 计划的目标是支持佐剂与临床相关疫苗/抗原平台相结合的并排比较，并建立系统和组织特异性免疫学特征（“免疫指纹”）通过不同机制发挥作用并对给定抗原和/或疾病靶点具有潜力的佐剂通过 ACC 计划支持，预计将： 1) 相互合作，包括使用标准化方案或终点检测； 2) 在 NIAID 的指导下筛选其他佐剂；3) 分享积极和消极的结果，以帮助指导该计划内和更广泛的科学界的基础研究和疫苗开发活动。研究将公开，以便合理选择佐剂以及未来开发更有效的传染病疫苗和/或治疗过敏或自身免疫性疾病的新疫苗。